<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919474</url>
  </required_header>
  <id_info>
    <org_study_id>HLariboisiere-ORL</org_study_id>
    <nct_id>NCT03919474</nct_id>
  </id_info>
  <brief_title>Blood Markers in Adult Patients With Sudden Sensorineural Hearing Loss (SSNHL)</brief_title>
  <acronym>SSNHL</acronym>
  <official_title>Markers of Microvascular Lesion in Adult Patients With Acquired Sudden Cochelo-vestibular Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Lariboisière</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Lariboisière</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The roles of thrombophilia and cardiovascular risk factors in sudden sensorineural hearing
      loss (SSNHL) remain controversial. Cochlear micro-thrombosis has been hypothesized as a
      possible pathogenic mechanism of SSNHL. The objective was thus to measure the levels of
      markers of macrovascular thrombosis and microvascular risk factors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To recruit adult consecutive outpatients referred for SSNHL to the otolaryngologist clinic of
      our university hospital starting June 2016 and prospectively until december 31th 2018.

      Plasma sampling and biomarkers quantification : After a 48-hours diet excluding serotonin-
      and tryptophan-rich food, fasting blood samples were collected into vacuum tubes containing
      109 mM sodium citrate (Becton-Dickinson, Le Pont de Claix, France) with a 9:1
      blood-to-anticoagulant ratio. After removing 0.5 mL of whole blood for serotonin
      measurements, the remainder was centrifuged at 1,000 x g for 10 minutes, and the supernatant
      was then centrifuged at 3,000 x g for 15 minutes to isolate platelets and obtain
      platelet-poor plasma. Importantly, the time between blood sampling and platelet/plasma
      isolation was less than one hour. Aliquots of whole blood, platelets, and plasma were kept
      frozen (-20°C) until serotonin and homocysteine measurements performed within one week after
      congelation. Whole blood, platelet and plasma 5-HT as well as plasma homocysteine (Hcy)
      levels were measured by high pressure liquid chromatography coupled to fluorimetric
      detections .

      Thrombophilia screening included measurements of antithrombin , protein C, protein S, factor
      V Leiden, prothrombin G20210A, methylene tetrahydrofolate reductase (MTHFR) C677T,
      antiphospholipid antibodies anticardiolipin IgG and IgM and anti-beta2 glycoprotein 1 IgG),
      dilute Russell viper venom time , Rosner index, factor VIII, von Willebrand factor (vWF)
      activity and antigen. Tests were performed on citrated plasma, serum or DNA as appropriate
      and as previously described
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>change from Baseline of plasma serotonin at three months</measure>
    <time_frame>at three months and then once a year up to five years</time_frame>
    <description>plasma serotonin level (HPLC, frequent value &lt;15nM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from Baseline of plasma homocystein at three months</measure>
    <time_frame>at three months and then once a year up to five years</time_frame>
    <description>plasma homocystein (HPLC, fequent value &lt;15 µM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from Baseline serum of anticardiolipine antibody at three months</measure>
    <time_frame>at three months and then once a year up to five years</time_frame>
    <description>serum anticardiolipin antiboy (ELISA, frequent value &lt;10units)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from Baseline of hearing characteristics at three months</measure>
    <time_frame>at three months and then once a year up to five years</time_frame>
    <description>audiogram</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Idiopathic SSNHL</condition>
  <condition>Age Over 18</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>microvascular markers</intervention_name>
    <description>follow up of microvascular biomarkers during patient follow up</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      venous peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        unrelated adult consecutive outpatients referred for SSNHL to the otolaryngologist clinic
        of our university hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult idiopathic SSNHL

        Exclusion Criteria:

          -  secundary hearing loss
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jean-marie Launay, PharmD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hopital Lariboisière</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ludovic 0 Drouet, MD, PhD</last_name>
    <phone>+33149956414</phone>
    <email>ludovic.drouet@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>charlotte Hautefort, MD</last_name>
    <phone>+33149958057</phone>
    <email>charlotte.hautefort@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HLariboisier otholaryngology clinic</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>charlotte Hautefort, MD</last_name>
      <phone>+331499958057</phone>
      <email>charlotte.hautefort@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Romain Kania, MD PhD</last_name>
      <phone>+331499956629</phone>
      <email>romain.kania@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>ludovic o Drouet, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Callebert J, Esteve JM, Hervé P, Peoc'h K, Tournois C, Drouet L, Launay JM, Maroteaux L. Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice. J Pharmacol Exp Ther. 2006 May;317(2):724-31. Epub 2006 Feb 3.</citation>
    <PMID>16461587</PMID>
  </reference>
  <results_reference>
    <citation>Brand T, Anderson GM. The measurement of platelet-poor plasma serotonin: a systematic review of prior reports and recommendations for improved analysis. Clin Chem. 2011 Oct;57(10):1376-86. doi: 10.1373/clinchem.2011.163824. Epub 2011 Aug 22. Review.</citation>
    <PMID>21859903</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hopital Lariboisière</investigator_affiliation>
    <investigator_full_name>Ludovic Drouet MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sudden hearing loss,</keyword>
  <keyword>SSNHL</keyword>
  <keyword>serotonin</keyword>
  <keyword>homocystein</keyword>
  <keyword>antiphospholipid syndrom</keyword>
  <keyword>thrombophilia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>it will be decided at completion of patient recruitement</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

